FDA Struggles to Meet Mandates Amidst Workforce Reductions

The U.S. FDA faces challenges in meeting product review deadlines due to layoffs mandated by the Trump administration. Scientists report an overwhelming workload, leading to delayed reviews and canceled projects. Concerns arise within the medical device industry about potential delays in bringing products to market.

U.S. health regulators, particularly the FDA, are grappling with meeting mandated deadlines for reviewing medical devices and tobacco products. This struggle stems from significant layoffs ordered by the Trump administration, according to scientists involved in these projects.

FDA scientists report an increased workload, having to manage double the number of new product applications after many colleagues were dismissed. This has forced them to deprioritize other vital tasks, raising concerns about longer evaluation times and potential oversight risks.

Medical and tobacco product sectors are concerned about delays impacting market entry due to resource constraints. Industry leaders and experts have voiced worries regarding missed deadlines, affecting high-profile projects like Philip Morris's heated tobacco device IQOS. The U.S. Department of Health and Human Services is considering further layoffs, adding to the uncertainty.

(With inputs from agencies.)